Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: A retrospective analysis of 939 liver biopsies in a single center

Liver Transplantation

Volumn 13, Issue 2, 2007, Pages 294-301

  Walter, Thomas ^a   Dumortier, Jérôme ^a   Guillaud, Olivier ^a   Hervieu, Valérie ^a   Scoazec, Jean Yves ^a   Boillot, Olivier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; ERYTHROPOIETIN; INTERFERON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; ASTHENIA; CHRONIC GRAFT REJECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG USE; FEMALE; GENDER BIAS; GRAFT RECIPIENT; HEART INFARCTION; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LINEAR SYSTEM; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; ORGAN DONOR; PRIORITY JOURNAL; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; SHORT COURSE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TIME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS;

EID: 33847653674     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21000     Document Type: Article

References (35)

1. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231-1243.
2. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-678.
3. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9(Suppl):S1-S9.
4. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9(Suppl):S28-S34.
5. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
6. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
7. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002:122:889-896.
8. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002:36:202-210.
9. Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant 2006;6:1398-1406.
10. Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004:10:868-871.
11. Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. Transpl Int 2005;17:759-766.
12. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004;10:199-207.
13. Boillot O, Berger F, Rasolofo E, Mion F, Chevallier P, Gille D, et al. Effects of early interferon alfa therapy for hepatitis C virus infection recurrence after liver transplantation. Transplant Proc 1995;27:2501.
14. Dumortier J, Scoazec JY, Berger F, Boillot O. Recurrence of hepatitis C after liver transplantation: follow-up and treatment. Transplant Proc 2002;34:779-781.
15. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004:40:669-674.
16. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
17. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
18. Sebagh M, Rifai K, Feray C, Yilmaz F, Falissard B, Roche B, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003:37:1293-1301.
19. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-663.
20. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000;31:792-799.
21. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
22. Rifai K, Sebagh M, Karam V, Saliba F, Azoulay D, Adam R, et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004;41:446-453.
23. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
24. Berenguer M, Rayon JM, Prieto M, Aguilera V, Nicolas D, Ortiz V, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001;7:790-796.
25. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995:108:1088-1096.
26. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006;12:1192-1204.
27. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
28. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
29. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
30. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12:51-57.
31. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7:1064-1070.
32. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-369.
33. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with micro-emulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65:1044-1046.
34. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-1247.
35. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003;12:642-650.